Progyny (NASDAQ: PGNY) is one of 27 publicly-traded companies in the “Miscellaneous health & allied services, not elsewhere classified” industry, but how does it weigh in compared to its peers? We will compare Progyny to related companies based on the strength of its risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.
This is a breakdown of recent recommendations for Progyny and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Volatility and Risk
Progyny has a beta of 1.82, suggesting that its stock price is 82% more volatile than the S&P 500. Comparatively, Progyny’s peers have a beta of 7.07, suggesting that their average stock price is 607% more volatile than the S&P 500.
This table compares Progyny and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Progyny and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Progyny||$344.86 million||$46.46 million||355.56|
|Progyny Competitors||$1.94 billion||$96.17 million||42.17|
Progyny’s peers have higher revenue and earnings than Progyny. Progyny is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Insider & Institutional Ownership
81.5% of Progyny shares are held by institutional investors. Comparatively, 43.2% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by institutional investors. 33.3% of Progyny shares are held by insiders. Comparatively, 26.4% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Progyny beats its peers on 8 of the 13 factors compared.
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.